（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致之任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd. * (股份代碼: 02607) 股東週年大會之投票結果 及 派發及收取現金紅利的登記日 一、 股東週年大會之投票結果 上海醫藥集團股份有限公司（「本公司」）2024年股東週年大會（「股東週年大會」）已於 2025年6月26日（星期四）下午一時正，假座中國上海市徐匯區楓林路450號楓林國際大廈二期 六樓裙樓601會議室舉行。 於股東週年大會上審議的決議案的詳情已載於本公司日期為2025年5月29日的股東週年大會通告 及股東週年大會通函（「通函」）。除非本公告另有界定，否則通函所用詞語在本公告中具有 相同涵義。 股東週年大會在符合《中華人民共和國公司法》及公司章程的規定下召開，並由本公司董事長 楊秋華先生擔任股東週年大會主席。根據香港上市規則的規定，本公司 ...

Core Viewpoint - Shanghai Pharmaceuticals has received the drug registration certificate for Pregabalin capsules from the Thai Food and Drug Administration, allowing the product to be marketed in Thailand [1][2]. Group 1: Drug Information - Drug Name: Pregabalin Capsules - Dosage Forms: Capsule - Specifications: 50mg, 75mg, 150mg - Registration Category: Chemical Generic Drug - Manufacturer: Changzhou Pharmaceutical Factory Co., Ltd. [1] - Registration Numbers: 50mg: 1C 97/68 (NG); 75mg: 1C 98/68 (NG); 150mg: 1C 99/68 (NG) [1]. Group 2: Indications - Pregabalin capsules are primarily used for treating postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, and neuropathic pain due to spinal cord injury, as well as for adjunctive treatment of epilepsy [1]. Group 3: Market Competition - As of the announcement date, Pregabalin capsules in Thailand face competition from 24 other sellers, including VIATRIS, SANDOZ, and BIOLAB [2]. - According to IQVIA data, the total market for Pregabalin capsules in Thailand is projected for 2024 [2]. Group 4: Financial Investment - The company has invested approximately RMB 2.19 million in research and development for the product's market entry in Southeast Asia, including Thailand, Singapore, Malaysia, and the Philippines [2]. Group 5: Impact on Company - The approval of Pregabalin capsules in three specifications (50mg, 75mg, 150mg) signifies the company's qualification to sell the drug in Thailand, positively impacting its overseas market expansion and accumulating valuable experience [2].

证券代码：601607 证券简称：上海医药 公告编号：临2025-062 上海医药集团股份有限公司 关于召开2024年年度股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海医药集团股份有限公司（以下简称"上海医药"、"公司"）于2025 年5月31日在《上海证券报》、《证券日报》、《证券时报》、《中国证券报》 和上海证券交易所网站（www.sse.com.cn）上刊登了《上海医药集团股份有限 公司关于召开2024年年度股东大会的通知》（临2025-059），定于2025年6月26 日以现场投票和网络投票相结合的方式召开2024年年度股东大会。现将本次会 议的有关事项提示如下: 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024年年度股东大会 1 股东大会召开日期：2025年6月26日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 召开地点：中国上海市徐汇区枫林路 450 号枫林国际大厦二期六楼裙楼 601 会议室 (五) 网络投票的系统、起止日期和投票 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-061 上海医药集团股份有限公司 关于持股5%以上股东权益变动触及1%刻度的提示性公告 控股股东及其一致行动人上实国际投资有限公司保证向本公司提供的信息真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 权益变动方向 比例增加? 比例减少□ 权益变动前合计比例 37.00% 权益变动后合计比例 38.03% 本次变动是否违反已作出的承 是□ 否? 诺、意向、计划 是否触发强制要约收购义务 是□ 否? 一、 信息披露义务人及其一致行动人的基本信息 ?控股股东/实际控制人及其一致行动人 □其他 5%以上大股东及其一致行动人 投资者及其一致行动人的身份 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人） □其他______________（请注明） 信息披露义务人名称 投资者身份 统一社会信用代码 □ 控股股东/实控人 上实国际投资有限公 ? 控股股东/实控人的一致 □ _____________ 司（以下简称"上实 行动人 ? 不适用 国际 ...

Core Viewpoint - Shanghai Pharmaceuticals has received approval for the production of Formoterol Fumarate Inhalation Solution, which is intended for the maintenance treatment of chronic obstructive pulmonary disease (COPD) [1][2]. Group 1: Drug Information - The drug is classified as a Class 3 chemical drug and is registered under the approval number H20254361 [1]. - The formulation is an inhalation solution with a specification of 2ml:20μg [1]. - The drug is indicated for maintaining airway obstruction in COPD patients, including chronic bronchitis and emphysema, to be administered twice daily [2]. - The product was originally developed by Mylan Specialty L.P. and was first approved in the U.S. in May 2007 under the brand name PERFOROMIST [2]. - As of the announcement date, the company has invested approximately RMB 4.4055 million in the research and development of this drug [2]. - The projected procurement amount for Formoterol Fumarate Inhalation Solution in Chinese hospitals for 2024 is RMB 461.55 million [2]. Group 2: Market Impact - The approval of this drug is expected to enhance market share and competitiveness for Shanghai Pharmaceuticals, as new registered generic drugs will receive greater support in medical insurance and procurement [3]. - The experience gained from this approval will be valuable for the company in future generic drug applications [3].

Core Insights - The AMAC Wholesale Retail Trade Index (AMAC批零, H11045) increased by 1.3%, closing at 1617.5 points with a trading volume of 31.254 billion [1] - Over the past month, the index has risen by 2.93%, by 1.85% over the last three months, and by 0.73% year-to-date [1] Index Composition - The AMAC Wholesale Retail Trade Index is based on 43 industry classification indices, excluding manufacturing, and is compiled according to the classification guidelines from the China Securities Association [1] - The top ten weighted stocks in the index are: Huadong Medicine (5.33%), Yonghui Supermarket (3.05%), Digital China (2.87%), Shanghai Pharmaceuticals (2.83%), Wancheng Group (2.26%), Wuchan Zhongda (2.21%), Yifeng Pharmacy (2.19%), Jiuzhoutong (1.83%), Sinopharm (1.58%), and Kidswant (1.57%) [1] Market Distribution - The market distribution of the AMAC Wholesale Retail Trade Index shows that the Shenzhen Stock Exchange accounts for 53.12%, while the Shanghai Stock Exchange accounts for 46.88% [1] Industry Breakdown - In terms of industry composition, discretionary consumption accounts for 36.90%, healthcare for 31.52%, industrials for 22.28%, staples for 4.58%, energy for 2.78%, real estate for 1.27%, and financials for 0.67% [2]

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Changzhou Pharmaceutical Factory, has received notification from the U.S. Food and Drug Administration (FDA) that its abbreviated new drug application (ANDA) for rivaroxaban tablets has been approved, which is significant for expanding the company's overseas market presence [1] Summary by Relevant Sections - **Drug Approval** - The FDA has approved the ANDA for rivaroxaban tablets, which are primarily used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] - **Application Timeline** - The ANDA application was submitted in December 2021, and the approval was recently granted [1] - **Research and Development Investment** - As of the announcement date, the company has invested approximately 8.2 million yuan in research and development for this drug [1] - **Market Potential** - In 2023, the sales revenue of rivaroxaban tablets in the U.S. was approximately 8.13 billion dollars, with projected sales of about 6.33 billion dollars for the first three quarters of 2024 [1] - **Strategic Importance** - The approval is expected to have a positive impact on the company's efforts to further penetrate the overseas market [1]

Core Viewpoint - The article emphasizes the importance of enhancing the quality of listed companies in Shanghai, focusing on cultivating high-performing, innovative, and well-governed firms that are recognized in the market [1][2]. Group 1: Shanghai State-owned Enterprises Performance - As of the end of 2024, the total market value of 94 state-owned listed companies in Shanghai reached 2.78 trillion yuan, an increase of 617.74 billion yuan, or 28.52% from the beginning of the year [1]. - The Shanghai Municipal State-owned Assets Supervision and Administration Commission aims to complete high-quality reforms and enhance the market value performance of state-owned listed companies [2]. Group 2: Company Highlights Shanghai Port Group - In 2024, Shanghai Port Group achieved a container throughput of 51.506 million TEUs, a year-on-year increase of 4.8%, maintaining its position as the world's largest port for 15 consecutive years [3]. - The company's net profit attributable to shareholders reached 14.95 billion yuan, a growth of 13.3% year-on-year [3]. Huayi Group - Huayi Group reported a revenue of 44.6 billion yuan in 2024, a 9.3% increase year-on-year, with a net profit of 0.91 billion yuan, up 5.8% [5]. - The company applied for 151 patents, receiving 134 authorizations, and is focusing on strategic emerging sectors [5][6]. Shanghai Pharmaceuticals - Shanghai Pharmaceuticals achieved a revenue of 275.251 billion yuan, a 5.75% increase, and a net profit of 4.553 billion yuan, up 20.82% [6][7]. - The company is optimizing its R&D system and has established a new innovation center to enhance its open innovation ecosystem [7]. Pudong Development Bank - Pudong Development Bank reported a net profit of 45.3 billion yuan in 2024, a 23.31% increase, marking the highest growth in nearly 12 years [9]. - The bank is focusing on technology finance and has developed a comprehensive cross-border financial service system [10][11]. China Pacific Insurance - China Pacific Insurance reported a revenue of 404.089 billion yuan, a 24.7% increase, and a net profit of 44.96 billion yuan, up 64.9% [11][12]. - The company is enhancing its green insurance offerings and has provided coverage exceeding 147 trillion yuan in green insurance [13]. Data Harbor - Data Harbor achieved a revenue of approximately 1.721 billion yuan, an 11.57% increase, and a net profit of approximately 132 million yuan, up 7.49% [14][15]. - The company is focusing on IDC services and has been recognized as a top service provider in the industry [14].

上海医药 SH Pharma (2607 HK) 2025 年一季度业绩：符合预期；医药商业创新业务增速瞩目 1Q25 results: in line; remarkable innovative pharmaceutical service business growth [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$10.74 目标价 HK$13.73 HTI ESG 4.2-4.4-3.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$63.18bn / US$8.15bn 日交易额 (3 个月均值) US$7.17mn 发行股票数目 919.07mn 自由流通股 (%) 74% 1 年股价最高最低值 HK$14.60-HK$10.12 注：现价 HK$10.64 为 2025 年 05 月 02 日收盘价 资料来源： Factset 1mth 3mth 12 ...

研究报告 Research Report 6 May 2025 点评 创新业务拉动医药商业板块持续稳健增长 2025 年一季度，上海医药实现营收 707.6 亿元，同比+0.9%。归母 净利润13.3亿元，同比-13.6%，主要受工业利润贡献下滑影响，部 分受一次性损失（3 月子公司上海信谊联合罚款损失约 1.66 亿元） 和资产处置损失约1000万元（去年同期为资产处置收益1.1亿元） 影响；扣非归母净利润 12.6 亿元，同比-8.1%。分板块看： 医药商业板块（分销+零售）：2025 年一季度实现收入 648.8 亿 元，同比+2.6%。我们认为在医药流通大环境整体复苏较慢的背景 下，上海医药的医药商业展现出较强的业绩韧性，主要由医药商 业创新业务拉动。药品合约销售 CSO 业务收入超 18 亿元，同比 +9.9%；创新药分销业务收入 125 亿元，同比+23.2%，其中进口总 代业务收入 86 亿元，同比+9.0%；器械大健康业务收入 109 亿元， 同比+6.9%。商业板块贡献利润 8.3 亿元，同比基本持平。 医药工业板块：2025 年一季度实现收入 58.9 亿元，同比-15.3% （主要受去年 ...